• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

EZH2 targeting induces CD38 upregulation and response to anti-CD38 immunotherapies in multiple myeloma.

作者信息

Chemlal Djamila, Varlet Emmanuel, Machura Amelie, Ovejero Sara, Requirand Guilhem, Robert Nicolas, Cartron Guillaume, Alaterre Elina, Bret Caroline, Vincent Laure, Herbaux Charles, Cavalli Giacomo, Bruyer Angélique, De Boussac Hugues, Moreaux Jerome

机构信息

Diag2Tec, Montpellier, France.

Institute of Human Genetics, UMR CNRS-UM, 9002, Montpellier, France.

出版信息

Leukemia. 2023 Sep;37(9):1925-1928. doi: 10.1038/s41375-023-01983-0. Epub 2023 Aug 2.

DOI:10.1038/s41375-023-01983-0
PMID:37532787
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10457196/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/46ca/10457196/6e41b9698724/41375_2023_1983_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/46ca/10457196/d86de040bbd1/41375_2023_1983_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/46ca/10457196/6e41b9698724/41375_2023_1983_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/46ca/10457196/d86de040bbd1/41375_2023_1983_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/46ca/10457196/6e41b9698724/41375_2023_1983_Fig2_HTML.jpg

相似文献

1
EZH2 targeting induces CD38 upregulation and response to anti-CD38 immunotherapies in multiple myeloma.靶向EZH2可诱导多发性骨髓瘤中CD38上调并增强对抗CD38免疫疗法的反应。
Leukemia. 2023 Sep;37(9):1925-1928. doi: 10.1038/s41375-023-01983-0. Epub 2023 Aug 2.
2
Targeting NAD Synthesis to Potentiate CD38-Based Immunotherapy of Multiple Myeloma.靶向 NAD 合成增强基于 CD38 的多发性骨髓瘤免疫治疗。
Trends Cancer. 2020 Jan;6(1):9-12. doi: 10.1016/j.trecan.2019.11.005. Epub 2019 Dec 31.
3
Editorial: Immunotherapy in Multiple Myeloma.社论：多发性骨髓瘤的免疫疗法
Front Immunol. 2019 Aug 14;10:1945. doi: 10.3389/fimmu.2019.01945. eCollection 2019.
4
DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma.DNA甲基转移酶抑制剂上调CD38蛋白表达并增强达雷妥尤单抗在多发性骨髓瘤中的疗效。
Leukemia. 2020 Mar;34(3):938-941. doi: 10.1038/s41375-019-0587-5. Epub 2019 Oct 8.
5
Novel Insights in Anti-CD38 Therapy Based on CD38-Receptor Expression and Function: The Multiple Myeloma Model.基于 CD38 受体表达和功能的抗 CD38 治疗新见解：多发性骨髓瘤模型。
Cells. 2020 Dec 11;9(12):2666. doi: 10.3390/cells9122666.
6
Loss of CD38 expression in myelomatous pleural effusion in a patient with myeloma treated with daratumumab: Report of a case.达雷妥尤单抗治疗的骨髓瘤患者出现骨髓瘤性胸腔积液中CD38表达缺失：一例报告
Diagn Cytopathol. 2021 Jan;49(1):168-170. doi: 10.1002/dc.24630. Epub 2020 Oct 1.
7
Preclinical Development of Near-Infrared-Labeled CD38-Targeted Daratumumab for Optical Imaging of CD38 in Multiple Myeloma.近红外标记的靶向 CD38 的达妥木单抗的临床前开发用于多发性骨髓瘤中 CD38 的光学成像。
Mol Imaging Biol. 2021 Apr;23(2):186-195. doi: 10.1007/s11307-020-01542-4. Epub 2020 Sep 22.
8
Evaluation of CD38 as target for immunotherapy in multiple myeloma.评估CD38作为多发性骨髓瘤免疫治疗靶点的研究
Blood. 1995 Apr 15;85(8):2282-4.
9
Daratumumab in multiple myeloma.达雷妥尤单抗在多发性骨髓瘤中的应用。
Cancer. 2019 Jul 15;125(14):2364-2382. doi: 10.1002/cncr.32065. Epub 2019 Apr 5.
10
Long-term CD38 saturation by daratumumab interferes with diagnostic myeloma cell detection.达雷妥尤单抗对CD38的长期饱和作用会干扰骨髓瘤细胞的诊断检测。
Haematologica. 2017 Sep;102(9):e368-e370. doi: 10.3324/haematol.2017.169235. Epub 2017 May 18.

引用本文的文献

1
Deciphering the bone marrow microenvironment's role in multiple myeloma immunotherapy resistance.解读骨髓微环境在多发性骨髓瘤免疫治疗耐药中的作用
Front Immunol. 2025 Jul 18;16:1613265. doi: 10.3389/fimmu.2025.1613265. eCollection 2025.
2
CD200 immune checkpoint expression is associated with inferior outcome in multiple myeloma patients treated with anti-CD38 monoclonal antibodies.CD200免疫检查点表达与接受抗CD38单克隆抗体治疗的多发性骨髓瘤患者的较差预后相关。
Oncoimmunology. 2025 Dec;14(1):2532226. doi: 10.1080/2162402X.2025.2532226. Epub 2025 Jul 20.
3
Exploring secondary extramedullary myeloma disease: a five-predictor scoring system with spotlight on double-hit cytogenetics.

本文引用的文献

1
Daratumumab in first-line therapy is cost-effective in transplant-eligible patients with newly diagnosed myeloma.达雷妥尤单抗作为一线治疗药物，在适合移植的新诊断多发性骨髓瘤患者中具有成本效益。
Blood. 2022 Aug 11;140(6):594-607. doi: 10.1182/blood.2021015220.
2
Comprehensive characterization of the epigenetic landscape in Multiple Myeloma.全面描绘多发性骨髓瘤的表观遗传学特征。
Theranostics. 2022 Jan 16;12(4):1715-1729. doi: 10.7150/thno.54453. eCollection 2022.
3
Tazemetostat: a treatment option for relapsed/refractory follicular lymphoma.
探索继发性髓外骨髓瘤疾病：一种聚焦双打击细胞遗传学的五预测因子评分系统。
BMC Med. 2025 May 2;23(1):257. doi: 10.1186/s12916-025-04086-y.
4
Spatial imaging unlocks the potential of charting multiple myeloma and extramedullary disease.空间成像揭示了绘制多发性骨髓瘤和髓外疾病图谱的潜力。
J Hematol Oncol. 2025 Apr 23;18(1):47. doi: 10.1186/s13045-025-01699-x.
5
The de novo DNA methyltransferase 3B is a novel epigenetic regulator of MYC in multiple myeloma, representing a promising therapeutic target to counter relapse.从头DNA甲基转移酶3B是多发性骨髓瘤中MYC的一种新型表观遗传调节剂，是对抗复发的一个有前景的治疗靶点。
J Exp Clin Cancer Res. 2025 Apr 17;44(1):125. doi: 10.1186/s13046-025-03382-y.
6
Transient loss of Polycomb components induces an epigenetic cancer fate.短暂丧失多梳成分会诱导表观遗传致癌命运。
Nature. 2024 May;629(8012):688-696. doi: 10.1038/s41586-024-07328-w. Epub 2024 Apr 24.
7
CD56 expression predicts response to Daratumumab-based regimens.CD56表达可预测基于达雷妥尤单抗方案的疗效。
Blood Cancer J. 2024 Apr 12;14(1):62. doi: 10.1038/s41408-024-01051-5.
8
Beyond the marrow: insights from comprehensive next-generation sequencing of extramedullary multiple myeloma tumors.超越骨髓：全面下一代测序对髓外多发性骨髓瘤肿瘤的深入见解。
Leukemia. 2024 Jun;38(6):1323-1333. doi: 10.1038/s41375-024-02206-w. Epub 2024 Mar 16.
他替莫唑胺：复发/难治性滤泡性淋巴瘤的治疗选择。
Expert Opin Pharmacother. 2022 Feb;23(3):295-301. doi: 10.1080/14656566.2021.2014815. Epub 2021 Dec 14.
4
Multiple myeloma.多发性骨髓瘤。
Lancet. 2021 Jan 30;397(10272):410-427. doi: 10.1016/S0140-6736(21)00135-5.
5
Replicational Dilution of H3K27me3 in Mammalian Cells and the Role of Poised Promoters.哺乳动物细胞中 H3K27me3 的复制稀释作用及其在启动子预先设定中的作用。
Mol Cell. 2020 Apr 2;78(1):141-151.e5. doi: 10.1016/j.molcel.2020.01.017. Epub 2020 Feb 5.
6
Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma.多发性骨髓瘤中抗 CD38 达雷妥尤单抗耐药的机制。
Cells. 2020 Jan 9;9(1):167. doi: 10.3390/cells9010167.
7
Statistical determination of synergy based on Bliss definition of drugs independence.基于 Bliss 定义的药物独立性，通过统计学方法确定协同作用。
PLoS One. 2019 Nov 25;14(11):e0224137. doi: 10.1371/journal.pone.0224137. eCollection 2019.
8
DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma.DNA甲基转移酶抑制剂上调CD38蛋白表达并增强达雷妥尤单抗在多发性骨髓瘤中的疗效。
Leukemia. 2020 Mar;34(3):938-941. doi: 10.1038/s41375-019-0587-5. Epub 2019 Oct 8.
9
EZH2 is overexpressed in transitional preplasmablasts and is involved in human plasma cell differentiation.EZH2 在过渡性前浆细胞中过表达，并参与人类浆细胞分化。
Leukemia. 2019 Aug;33(8):2047-2060. doi: 10.1038/s41375-019-0392-1. Epub 2019 Feb 12.
10
CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance.CD38 抗体在多发性骨髓瘤中的作用机制和耐药模式。
Front Immunol. 2018 Sep 20;9:2134. doi: 10.3389/fimmu.2018.02134. eCollection 2018.